DATAGUARD
5.6.2024 17:29:34 CEST | Business Wire | Press release
DataGuard, a leading Software-as-a-Service (SaaS) company for security and compliance, announced today that it has acquired DPOrganizer. This acquisition expands DataGuard’s footprint particularly in the Nordic region and the UK, and strengthens the company’s market position across its core geographies Europe and North America. DataGuard helps over 4,000 customers active in more than 50 countries build robust security and compliance management systems. Companies use DataGuard’s software platform to get certified and become compliant with frameworks (such as GDPR, CCPA, ISO 27001, NIS 2, or SOC 2) as well as manage their most important risks efficiently, thereby staying ahead of evolving business and regulatory needs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240605633259/en/
Security & Compliance Management Software (Photo: Business Wire)
DPOrganizer, a Stockholm-based privacy management solution for privacy professionals and in-house data protection and compliance teams, helps small and large customers in more than 20 countries build and run effective privacy programs, comply with regulation, and build trust with their customers and partners. DPOrganizer’s powerful software toolkit offers incidents and breach management, data subject request handling, data protection impact assessments, and more functionalities. Thanks to the advanced data mapping, analytics and data flow visualization capabilities, data protection officers and privacy professionals can ensure collection and retention of data in line with regulation and best practice, identifying patterns and anomalies, and preventing breaches or non-compliance.
"Today’s announcement is a major milestone on DataGuard’s growth journey. Integrating DPOrganizer’s capabilities will enhance our offering for customers. It helps us build a unique system-of-record for the security and compliance domain that lets companies go beyond certifications and tick-the-box exercises,” says Thomas Regier, co-founder and co-CEO at DataGuard. “This and our comprehensive risk-first approach give DataGuard an asymmetric advantage as we transition into the era of AI-piloted security and compliance programs. We will continue to integrate strategic tech partners natively into our software ecosystem – to further broaden our customer value proposition and expand our geographic footprint.”
“In the era of data and artificial intelligence, organisations are constantly exposed to an increasing number of cyber threats and are required to comply with a multitude of frameworks to continue their business operations. As we know from our customers, ‘the risk is real’, and we believe the best way to address this is to have an effective digital information security and compliance management system. Partnering with DPOrganizer helps us further this mission,” said Kivanc Semen, co-founder and co-CEO at DataGuard.
“DPOrganizer was built for and is loved by privacy and compliance professionals. By joining forces with DataGuard, we can add capabilities such as the AI copilot, asset management, risk and controls management, and numerous information security frameworks. We thereby enable customers to build the bridge between security and compliance, expert and non-expert, business and compliance people. I am beyond excited to start this joint journey and combine our deep domain expertise and technological capabilities. We will continue to give thousands of customers a best-in-class experience,” Egil Bergenlind, co-founder of DPOrganizer summarizes.
About DataGuard
DataGuard is a security and compliance software company trusted by more than 4,000 organisations across the globe. Customers use the platform to build up a scalable risk management and a strong security posture while getting certified fast and complying effortlessly with industry regulation and frameworks such as ISO 27001, TISAX®, NIS2, SOC2, GDPR, and the EU Whistleblower Directive. Our purpose-built software suite offers AI-powered workflow automation and seamless integration capabilities, reducing the time and money organisations spend to build a digital Information Security Management System (ISMS) and Compliance Management System (CMS). DataGuard empowers organisations active in 50+ countries to better understand, identify, and manage the risks that matter most to them – and to build up a robust security and compliance posture that allows them to stay ahead of their evolving business and regulatory needs.
About DPOrganizer
DPOrganizer is a market leading provider of privacy management software that helps privacy professionals in 20+ countries to build more effective and sustainable data protection programs. The company offers an intuitive and easy to use software supporting customers with data mapping, assessment automation, reporting and visualization, data protection trainings, data subject request and incident management.
TISAX® is a registered trademark of the ENX Association. DataGuard is not affiliated with the ENX Association.
We provide Software-as-a-Service and support for the assessment on TISAX® only.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240605633259/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom